NEWS ON THE NON ALCOHOLIC STEATOHEPATITIS DISEASE, ACTORS AND FUTURES TREATMENTS !  


 Click on the picture details to enter or use the upper menu !


NASHDAY

NEWS


LAST NEWS

2018-06-11 : A critical review of endpoints for non-cirrhotic NASH therapeutic trials

2018-05-31 : Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial

2018-04-18 : Novartis expands development programs for NASH through clinical collaboration with Allergan

2018-04-11 : GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort

2018-04-05 : Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

2018-04-04 : Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality

2018-04-03 : MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

2018-04-03 : Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis

2018-03-22 : A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

2018-03-22 : High Consumption of Red and Processed Meats May Lead to Non-alcoholic Liver Disease

2018-03-21 : Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients

2018-03-19 : Aortic carboxypeptidase–like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis

2018-03-19 : Diabetes medicine reduces liver fat in nonalcoholic fatty liver disease

2018-03-09 : A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis

2018-03-08 : Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis

2018-03-07 : Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux

2018-03-07 : Immuron Reports Positive Results in NASH Clinical Trial

2018-02-28 : Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

2018-02-27 : Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018

2018-02-27 : NASH rapidly overtaking hepatitis C as cause of liver cancer

2018-02-21 : Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis

2018-02-18 : The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease

2018-02-01 : Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

2018-02-01 : FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease

2018-01-26 : Obeticholic Acid Monotherapy Leads to Jaundice in PBC Patient

2018-01-23 : GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA

2018-01-17 : Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease

2018-01-04 : 4 to 6 january 2018 the NASH TAG Conference in UTAH

2018-01-04 : Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)

2017-12-22 : Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

2017-12-21 : Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program

2017-12-20 : Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study

2017-12-06 : Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial

2017-12-04 : Targeting bile acids and lipotoxicity for NASH treatment

2017-11-23 : Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

2017-11-18 : Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients

2017-11-17 : PNPLA3 variant and portal/ periportal histological pattern in patients with biopsy-proven non- alcoholic fatty liver disease: a possible role for oxidative stress

2017-11-17 : Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization

2017-11-17 : Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance

2017-11-12 : Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease

2017-11-11 : Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

2017-11-06 : Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression

2017-11-06 : Obesity correlates with discordance in noninvasive tests for fibrosis

2017-11-03 : Article | OPEN Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors

2017-11-02 : Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)

2017-10-24 : Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)

2017-10-24 : Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

2017-10-24 : VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds...vs ELAFIBRANOR

2017-10-17 : An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease

2017-10-11 : Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

2017-10-06 : Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board

2017-10-05 : Galmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD

2017-10-01 : Comparative metabolic and hepatic effects of liraglutide, elafibranor and obeticholic acid in diet- induced and genetically obese mouse models of biopsy-confirmed NASH

2017-09-26 : Intercept Pharmaceuticals Inc said OCALIVA could carry a BOXED WARNING ! but no restrictions

2017-09-25 : Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients

2017-09-22 : New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial

2017-09-21 : FDA SAFETY ALERT ON OCALIVA IN PBC WILL UNDOUBTEDLY IMPACT NASH

2017-09-20 : FDA Issues Warning on Liver Injury from Intercept Pharma's (ICPT) Ocaliva

2017-09-18 : Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

2017-09-12 : IMPORTANT PRESCRIBING INFORMATION SUBJECT: Liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis (PBC) patients with moderate or severe hepatic impairment (Child-Pugh B and C) when OCALIVA® was dosed more frequently than recommended

2017-09-11 : Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

2017-09-06 : Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH

2017-09-05 : Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B

2017-09-04 : Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis

2017-08-28 : Study Offers New Targets for Drugs Against Fatty Liver Disease and Liver Cancer

2017-08-22 : Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis

2017-08-19 : SEMAGLUTIDE PERSPECTIVES IN NASH

2017-08-16 : NASH Summit Europe 10-12 October, 2017 Frankfurt, Germany is Europe’s definitive forum which exists to solve the challenges drug developers face from discovery to late stage clinical development.

2017-08-14 : Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

2017-08-01 : Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH

2017-06-23 : GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH

2017-06-20 : Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

2017-06-12 : Regulus hit as AstraZeneca hands back rights to one drug, R&D revamp culls two more

2017-06-08 : Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH

2017-06-05 : Non-alcoholic steatohepatitis (NASH); metabolic syndrome Patient sample, mouse and non-human primate (NHP) studies suggest that enhancing TMBIM1 expression could help treat non-alcoholic steatohepatitis (NASH) and metabolic syndrome

2017-06-02 : New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

2017-06-01 : GENFIT: Positive Outcome from the 1-year Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor

2017-06-01 : On May26, 2017, the Data and Safety Monitoring Committee (the DSMC) for clinical studies of Madrigal Pharmaceuticals,Inc.'s (the Company) MGL-3196, for the treatment of non-alcoholic steatohepatitis, held a pre-scheduled meeting to review data from the Company's Phase 2 clinical NASH trial.

2017-05-11 : Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2017-05-03 : Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

2017-04-24 : GENFIT : the recruitment of the 1000 first patients of RESOLV'IT will be delayed to T1 2018

2017-04-23 : NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

2017-04-21 : Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

2017-04-20 : Cerenis Therapeutics Announces the Initiation of the Phase 1 Clinical Study with CER-209 in NAFLD and NASH

2017-04-19 : Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

2017-03-29 : Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

2017-03-28 : GENFIT to host a series of KOL Meetings in NASH

2017-03-02 : RUMOR NOVARTIS COULD BE INTERESTED BY GENFIT

2017-02-28 : Cempra\'s solithromycin fails to match standard of care in GC study, development in NASH suspended

2017-02-17 : CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

2017-02-10 : The 10 of february, 2017 INTERCEPT Announced a modification of the protocole and endpoints, theu say it was done with the endorsement of the FDA and will increase their chance of success, ate this time we do not know the changes in detail . if the reversion definition vas modified to fulfill with the one used by GENFIT , it id definitively not a good news for OCALIVA, they never reached it in the previous studies.

2017-02-06 : Immuron enrols first patient in paediatric fatty liver trial in the U.S.

2017-02-02 : Inventiva launches its initial public offering on the regulated market of Euronext Paris

2017-01-24 : TOBIRA-ALLERGAN- launch STELLARIS: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

2017-01-09 : Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

2017-01-09 : Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study

2017-01-09 : Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical StudyCompany Plans to Launch a Clinical Development Program in NAFLDNASH in 2017 based on Gemcabene’s Lipid-Lowering and Inflammation Mechanism of Action

2017-01-05 : Phenex Pharmaceuticals AG Receives $100M Milestone Payment From Gilead (GILD)

2017-01-03 : Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2016-12-19 : Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

2016-12-16 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2016-12-07 : NASH DeMili Test is online (http://www.demilitest.com)

2016-11-14 : Genfit initiates paediatric NAFLD/NASH program in Europe

2016-11-14 : Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016

2016-11-02 : Gilead stated that no further development of simtuzumab will be pursued

2016-09-27 : GENFIT is Filing for IND Submission for New Indication of Elafibranor in Primary Biliary Cholangitis (PBC)

2016-09-25 : GALECTIN Ph2a NASH FX TRIAL FAIL ! STILL IN THE RACE WITH ONGOING NASH CX TRIAL

2016-09-20 : GENFIT: Significant Milestones Achieved under a New Qualification Program of Proprietary miRNAs and Algorithms for a Non-invasive NASH Diagnostic

2016-09-20 : Allergan buy TOBIRA for 1.7 billion $

2016-08-22 : Avolynt, Inc. Announces FDA Acceptance of IND to Commence Pivotal Trial of Remogliflozin for NASH

2016-08-20 : The NAFLD induced cost in 5 country (USA,UK,Italy,Germany, France) is close to 140 Billon $

2016-08-02 : Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

2016-07-29 : Shire receives FDA Fast Track for Volixibat on NASH with fibrosis

2016-07-14 : Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year

2016-04-21 : The full publication of GENFIT GOLDEN results are Published in Gastroenterology

2016-04-21 : A very good overview on NASH and PBC trials by Mary E. Rinella

2016-04-12 : Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

2016-04-04 : GILEAD Announces Aquisition of Nimbus Therapeutic -Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases -

2016-03-30 : Aramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

2016-01-15 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2015-10-29 : OCA fails to meet primary endpoint in Japanese patients with NASH

2014-08-24 : Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A)

2014-01-29 : Preclinical data support anti-cancer effects of GFT505










WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE